Cost-effectiveness of Dostarlimab Plus Carboplatin-Paclitaxel for Primary Advanced or Recurrent Endometrial Cancer from a US Payer Perspective.
GYNECOLOGIC ONCOLOGY（2025）
Key words
Dostarlimab,Endometrial cancer,Carboplatin-paclitaxel,Cost-effectiveness model
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined